Phosphoric Acid

Phosphoric Acid

SCHEMBL160588

O=P(O)(O)O.O=S(=O)(O)O.[AlH3]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA5A P35218 2/20 0.55
CA5B Q9Y2D0 2/20 0.55
TSHR P16473 3/20 0.36
CA2 P00918 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
CA1 P00915 1/20 0.36
NT5E P21589 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
BLM P54132 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC34A1 Q06495 1/20 0.33
MMP2 P08253 1/20 0.31
THRB P10828 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL28183362 1.00 CA5A (0.55) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL27899126 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28060649 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28268676 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL8061506 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL6231084 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL2345894 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL4455645 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28273311 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28104063 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2312 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746906-A1 IMMUNOGENIC COMPOSITIONS CONTAINING INACTIVATED INFLUENZA A VIRUS AND CPG OLIGONUCLEOTIDE ADJUVANT AND USES THEREOF Icahn School of Medicine at Mount Sinai (US) 2026-05-27 EP claimed
EP-4743109-A1 LYME DISEASE VACCINES COMPRISING AN ADJUVANT AND A BORRELIA OUTER SURFACE PROTEIN A ANTIGEN Dynavax Technologies Corporation (US) 2026-05-20 EP claimed
EP-4743110-A1 LYME DISEASE VACCINES COMPRISING AN ADJUVANT AND BORRELIA OUTER SURFACE PROTEIN A AND C ANTIGENS Dynavax Technologies Corporation (US) 2026-05-20 EP claimed
CN-122029130-A Precipitated aluminium hydroxide spheres and method for producing same 赢创运营有限公司 2026-05-12 CN claimed
US-12589144-B2 Combined norovirus and rotavirus vaccine composition and methods of preparation BHARAT BIOTECH INTERNATIONAL LIMITED (IN) 2026-03-31 US claimed
US-12582711-B2 RNA-based adjuvant to enhance the immune response to vaccines and therapeutics ImmuneSure LLC (US) 2026-03-24 US claimed
US-12569553-B2 Shingles vaccines comprising a TLR9 agonist DYNAVAX TECHNOLOGIES CORPORATION (US) 2026-03-10 US claimed
EP-4684013-A1 NON-HUMAN ANIMALS COMPRISING A GENETICALLY MODIFIED ENDOGENOUS IGHA LOCUS AND METHODS OF MAKING THE SAME Peking University First Hospital (CN) 2026-01-28 EP claimed
US-20250367277-A1 STREPTOCOCCAL VACCINES AND METHODS FOR USE GPN Vaccines Ltd (AU) 2025-12-04 US claimed
US-20250360190-A1 IMMUNOGENICITY OF A CPG-ADJUVANTED RECOMBINANT PLAGUE VACCINE DYNAVAX TECHNOLOGIES CORPORATION (US) 2025-11-27 US claimed
EP-2621530-A2 IMPROVED ADJUVANT SYSTEM FOR VACCINE ADMINISTRATION Vaxform LLC (US) 2013-08-07 EP claimed
EP-2621524-A1 IMPROVED VACCINE COMPOSITIONS Eurocine Vaccines AB (SE) 2013-08-07 EP claimed
EP-2129394-B1 PAPILLOMAVIRUS VACCINE COMPOSITIONS MERCK SHARP & DOHME (US) 2012-06-20 EP claimed
WO-2012047265-A2 IMPROVED ADJUVANT SYSTEM FOR VACCINE ADMINISTRATION VAXFORM LLC (US) 2012-04-12 WO claimed
WO-2012042003-A1 IMPROVED VACCINE COMPOSITIONS EUROCINE VACCINES AB (SE) 2012-04-05 WO claimed
US-7763359-B2 Reacting phosphoric acid, aluminum sulfate, and sodium hydroxide to form a precipitate, drying the precipitate to form amorphous aluminum ortho-phosphate particles having closed voids, and coating the particles with a binder; substitute for titanium dioxide in waterbased paints BUNGE FERTILIZANTES S.A. (BR) 2010-07-27 US claimed
US-7709010-B2 Papillomavirus vaccine compositions MERCK SHARP & DOHME CORP. (US) 2010-05-04 US claimed
EP-2129394-A1 PAPILLOMAVIRUS VACCINE COMPOSITIONS Merck & Co., Inc. (US) 2009-12-09 EP claimed
US-20080248062-A1 Papillomavirus vaccine compositions MERCK SHARP & DOHME LLC 2008-10-09 US claimed
WO-2008112125-A1 PAPILLOMAVIRUS VACCINE COMPOSITIONS MERCK & CO., INC. (US) 2008-09-18 WO claimed